|
1
|
Strauss SJ, Frezza AM, Abecassis N, Bajpai
J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot I, et
al: Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical
practice guideline for diagnosis, treatment and follow-up. Ann
Oncol. 32:1520–1536. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
3
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Behjati S, Tarpey PS, Sheldon H,
Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke
SL, Pillay N, et al: Recurrent PTPRB and PLCG1 mutations in
angiosarcoma. Nat Genet. 46:376–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marina NM, Smeland S, Bielack SS,
Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H,
Brennan B, et al: Comparison of MAPIE versus MAP in patients with a
poor response to preoperative chemotherapy for newly diagnosed
high-grade osteosarcoma (EURAMOS-1): An open-label, international,
randomised controlled trial. Lancet Oncol. 17:1396–1408. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ,
Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et
al: Ewing sarcoma: Current management and future approaches through
collaboration. J Clin Oncol. 33:3036–3046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Maldegem AM, Gelderblom H, Palmerini
E, Dijkstra SD, Gambarotti M, Ruggieri P, Nout RA, van de Sande MA,
Ferrari C, Ferrari S, et al: Outcome of advanced, unresectable
conventional central chondrosarcoma. Cancer. 120:3159–3164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakano K: Challenges of systemic therapy
investigations for bone sarcomas. Int J Mol Sci. 23:35402022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tlemsani C, Larousserie F, De Percin S,
Audard V, Hadjadj D, Chen J, Biau D, Anract P, Terris B, Goldwasser
F, et al: Biology and management of high-grade chondrosarcoma: An
Update on targets and treatment options. Int J Mol Sci.
24:13612023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu
X, Zhang Z, Yang S and Xiao M: Extracellular matrix remodeling in
tumor progression and immune escape: From mechanisms to treatments.
Mol Cancer. 22:482023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naser R, Fakhoury I, El-Fouani A,
Abi-Habib R and El-Sibai M: Role of the tumor microenvironment in
cancer hallmarks and targeted therapy (Review). Int J Oncol.
62:232023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alfranca A, Martinez-Cruzado L, Tornin J,
Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J and
Rodriguez R: Bone microenvironment signals in osteosarcoma
development. Cell Mol Life Sci. 72:3097–3113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Yang D, Yang Q, Lv X, Huang W,
Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, et al: Single-cell RNA
landscape of intratumoral heterogeneity and immunosuppressive
microenvironment in advanced osteosarcoma. Nat Commun. 11:63222020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicolas-Boluda A, Vaquero J, Vimeux L,
Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula
P, Pogoda K, et al: Tumor stiffening reversion through collagen
crosslinking inhibition improves T cell migration and anti-PD-1
treatment. Elife. 10:e586882021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shurin MR and Umansky V: Cross-talk
between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy.
J Clin Invest. 132:e1594732022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jinushi M, Chiba S, Yoshiyama H, Masutomi
K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A and Tahara H:
Tumor-associated macrophages regulate tumorigenicity and anticancer
drug responses of cancer stem/initiating cells. Proc Natl Acad Sci
USA. 108:12425–12430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saito M, Ichikawa J, Ando T, Schoenecker
JG, Ohba T, Koyama K, Suzuki-Inoue K and Haro H: Platelet-derived
TGF-β induces tissue factor expression via the smad3 pathway in
osteosarcoma cells. J Bone Miner Res. 33:2048–2058. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiratsuka S, Watanabe A, Sakurai Y,
Akashi-Takamura S, Ishibashi S, Miyake K, Shibuya M, Akira S,
Aburatani H and Maru Y: The S100A8-serum amyloid A3-TLR4 paracrine
cascade establishes a pre-metastatic phase. Nat Cell Biol.
10:1349–1355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Li J, Yang X, Li X, Kong J, Qi D,
Zhang F, Sun B, Liu Y and Liu T: Carcinoma-associated
fibroblast-derived lysyl oxidase-rich extracellular vesicles
mediate collagen crosslinking and promote epithelial-mesenchymal
transition via p-FAK/p-paxillin/YAP signaling. Int J Oral Sci.
15:322023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chevrier S, Crowell HL, Zanotelli VRT,
Engler S, Robinson MD and Bodenmiller B: Compensation of signal
spillover in suspension and imaging mass cytometry. Cell Syst.
6:612–620.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Umezu T, Tadokoro H, Azuma K, Yoshizawa S,
Ohyashiki K and Ohyashiki JH: Exosomal miR-135b shed from hypoxic
multiple myeloma cells enhances angiogenesis by targeting
factor-inhibiting HIF-1. Blood. 124:3748–3757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Principe DR, Kamath SD, Korc M and Munshi
HG: The immune modifying effects of chemotherapy and advances in
chemo-immunotherapy. Pharmacol Ther. 236:1081112022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han C, Liu Z, Zhang Y, Shen A, Dong C,
Zhang A, Moore C, Ren Z, Lu C, Cao X, et al: Tumor cells suppress
radiation-induced immunity by hijacking caspase 9 signaling. Nat
Immunol. 21:546–554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu Y, Li K, Peng Y, Zhang Z, Pu F, Shao Z
and Wu W: Tumor microenvironment in osteosarcoma: From cellular
mechanism to clinical therapy. Genes Dis. 12:1015692025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dutour A, Pasello M, Farrow L, Amer MH,
Entz-Werlé N, Nathrath M, Scotlandi K, Mittnacht S and
Gomez-Mascard A: Microenvironment matters: Insights from the FOSTER
consortium on microenvironment-driven approaches to osteosarcoma
therapy. Cancer Metastasis Rev. 44:442025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azizi E, Carr AJ, Plitas G, Cornish AE,
Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V and Setty
M: Single-Cell map of diverse immune phenotypes in the breast tumor
microenvironment. Cell. 174:1293–1308.e36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun CY, Zhang Z, Tao L, Xu FF, Li HY,
Zhang HY and Liu W: T cell exhaustion drives osteosarcoma
pathogenesis. Ann Transl Med. 9:14472021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visser LL, Bleijs M, Margaritis T, van de
Wetering M, Holstege FCP and Clevers H: Ewing sarcoma single-cell
transcriptome analysis reveals functionally impaired
antigen-presenting cells. Cancer Res Commun. 3:2158–2169. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guimarães GR, Maklouf GR, Teixeira CE, de
Oliveira Santos L, Tessarollo NG, de Toledo NE, Serain AF, de Lanna
CA, Pretti MA, da Cruz JGV, et al: Single-cell resolution
characterization of myeloid-derived cell states with implication in
cancer outcome. Nat Commun. 15:56942024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kashfi K, Kannikal J and Nath N:
Macrophage reprogramming and cancer therapeutics: Role of
iNOS-Derived NO. Cells. 10:31942021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ka HI, Mun SH, Han S and Yang Y: Targeting
myeloid-derived suppressor cells in the tumor microenvironment:
Potential therapeutic approaches for osteosarcoma. Oncol Res.
33:519–531. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao L, Liu P, Mao M, Zhang S, Bigenwald
C, Dutertre CA, Lehmann CHK, Pan H, Paulhan N, Amon L, et al: BCL2
inhibition reveals a dendritic cell-specific immune checkpoint that
controls tumor immunosurveillance. Cancer Discov. 13:2448–2469.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shaim H, Shanley M, Basar R, Daher M,
Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, et
al: Targeting the αv integrin/TGF-β axis improves natural killer
cell function against glioblastoma stem cells. J Clin Invest.
131:e421162021. View Article : Google Scholar
|
|
34
|
Tran HC, Wan Z, Sheard MA, Sun J, Jackson
JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, et al: TGFβR1
blockade with galunisertib (LY2157299) enhances anti-neuroblastoma
activity of the anti-GD2 antibody dinutuximab (ch14.18) with
natural killer cells. Clin Cancer Res. 23:804–813. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cao JW, Lake J, Impastato R, Chow L, Perez
L, Chubb L, Kurihara J, Verneris MR and Dow S: Targeting
osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2
Co-expression on functional activity. Cancer Immunol Immunother.
73:772024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Zhang Z, Liu G, Li D, Gu Z, Zhang
L, Pan Y, Cui X, Wang L, Liu G, et al: B7-H3 targeted CAR-T cells
show highly efficient anti-tumor function against osteosarcoma both
in vitro and in vivo. BMC Cancer. 22:11242022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fotsitzoudis C, Koulouridi A, Messaritakis
I, Konstantinidis T, Gouvas N, Tsiaoussis J and Souglakos J:
Cancer-associated fibroblasts: The origin, biological
characteristics and role in cancer-a glance on colorectal cancer.
Cancers (Basel). 14:43942022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cao Z, Quazi S, Arora S, Osellame LD,
Burvenich IJ, Janes PW and Scott AM: Cancer-associated fibroblasts
as therapeutic targets for cancer: Advances, challenges, and future
prospects. J Biomed Sci. 32:72025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Long AH, Highfill SL, Cui Y, Smith JP,
Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas
RJ and Mackall CL: Reduction of MDSCs with all-trans retinoic acid
improves CAR therapy efficacy for sarcomas. Cancer Immunol Res.
4:869–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Calvi LM, Adams GB, Weibrecht KW, Weber
JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P,
Bringhurst FR, et al: Osteoblastic cells regulate the
haematopoietic stem cell niche. Nature. 425:841–846. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang S, Greenbaum J, Qiu C, Gong Y, Wang
Z, Lin X, Liu Y, He P, Meng X, Zhang Q, et al: Single-cell RNA
sequencing reveals in vivo osteoimmunology interactions between the
immune and skeletal systems. Front Endocrinol (Lausanne).
14:11075112023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Canon JR, Roudier M, Bryant R, Morony S,
Stolina M, Kostenuik PJ and Dougall WC: Inhibition of RANKL blocks
skeletal tumor progression and improves survival in a mouse model
of breast cancer bone metastasis. Clin Exp Metastasis. 25:119–129.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kiesel JR, Buchwald ZS and Aurora R:
Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J
Immunol. 182:5477–5487. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Panagi M, Mpekris F, Voutouri C,
Hadjigeorgiou AG, Symeonidou C, Porfyriou E, Michael C, Stylianou
A, Martin JD, Cabral H, et al: Stabilizing tumor-resident mast
cells restores T-cell infiltration and sensitizes sarcomas to PD-L1
inhibition. Clin Cancer Res. 30:2582–2597. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Białas M, Dyduch G, Dudała J,
Bereza-Buziak M, Hubalewska-Dydejczyk A, Budzyński A and Okoń K:
Study of microvessel density and the expression of vascular
endothelial growth factors in adrenal gland pheochromocytomas. Int
J Endocrinol. 2014:1041292014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA and Camphausen K: Phase
II trial of single-agent bevacizumab followed by bevacizumab plus
irinotecan at tumor progression in recurrent glioblastoma. J Clin
Oncol. 27:740–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dong X, Ren J, Amoozgar Z, Lee S, Datta M,
Roberge S, Duquette M, Fukumura D and Jain RK: Anti-VEGF therapy
improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic
glioblastoma models in mice. J Immunother Cancer. 11:e0055832023.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Karnoub AE, Dash AB, Vo AP, Sullivan A,
Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg
RA: Mesenchymal stem cells within tumour stroma promote breast
cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trabanelli S, Lecciso M, Salvestrini V,
Cavo M, Očadlíková D, Lemoli RM and Curti A: PGE2-induced IDO1
inhibits the capacity of fully mature DCs to elicit an in vitro
antileukemic immune response. J Immunol Res. 2015:2531912015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zelenay S, van der Veen AG, Böttcher JP,
Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais
R, Quezada SA, et al: Cyclooxygenase-dependent tumor growth through
evasion of immunity. Cell. 162:1257–1270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kolb AD and Bussard KM: The bone
extracellular matrix as an ideal milieu for cancer cell metastases.
Cancers (Basel). 11:10202019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Molina ER, Chim LK, Salazar MC, Mehta SM,
Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D,
Zaske AM, et al: Mechanically tunable coaxial electrospun models of
YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta
Biomater. 100:38–51. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu D, Peng Y, Li X, Zhu Z, Mi Z, Zhang Z
and Fan H: Comprehensive landscape of TGFβ-related signature in
osteosarcoma for predicting prognosis, immune characteristics, and
therapeutic response. J Bone Oncol. 40:1004842023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Highfill SL, Cui Y, Giles AJ, Smith JP,
Zhang H, Morse E, Kaplan RN and Mackall CL: Disruption of
CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Sci Transl Med. 6:237ra672014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao TT, Zhou TJ, Zhang C, Liu YX, Wang
WJ, Li C, Xing L and Jiang HL: Hypoxia inhibitor combined with
chemotherapeutic agents for antitumor and antimetastatic efficacy
against osteosarcoma. Mol Pharm. 20:2612–2623. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Khojastehnezhad MA, Seyedi SMR, Raoufi F
and Asoodeh A: Association of hypoxia-inducible factor 1
expressions with prognosis role as a survival prognostic biomarker
in the patients with osteosarcoma: A meta-analysis. Expert Rev Mol
Diagn. 22:1099–1106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shi W, Cassmann TJ, Bhagwate AV, Hitosugi
T and Ip WKE: Lactic acid induces transcriptional repression of
macrophage inflammatory response via histone acetylation. Cell Rep.
43:1137462024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hashim AI, Cornnell HH, Mde LC, Abrahams
D, Cunningham J, Lloyd M, Martinez GV, Gatenby RA and Gillies RJ:
Reduction of metastasis using a non-volatile buffer. Clin Exp
Metastasis. 28:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Aquino A and Franzese O: Reciprocal
modulation of tumour and immune cell motility: Uncovering dynamic
interplays and therapeutic approaches. Cancers (Basel).
17:15472025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cui J, Dean D, Hornicek FJ, Chen Z and
Duan Z: The role of extracelluar matrix in osteosarcoma progression
and metastasis. J Exp Clin Cancer Res. 39:1782020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu W, Hu H, Shao Z, Lv X, Zhang Z, Deng
X, Song Q, Han Y, Guo T, Xiong L, et al: Characterizing the tumor
microenvironment at the single-cell level reveals a novel immune
evasion mechanism in osteosarcoma. Bone Res. 11:42023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gorchs L, Oosthoek M, Yucel-Lindberg T,
Moro CF and Kaipe H: Chemokine receptor expression on T cells is
modulated by CAFs and chemokines affect the spatial distribution of
T cells in pancreatic tumors. Cancers (Basel). 14:38262022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Park HK, Kim M, Sung M, Lee SE, Kim YJ and
Choi YL: Status of programmed death-ligand 1 expression in
sarcomas. J Transl Med. 16:3032018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yang R, Sun L, Li CF, Wang YH, Yao J, Li
H, Yan M, Chang WC, Hsu JM, Cha JH, et al: Galectin-9 interacts
with PD-1 and TIM-3 to regulate T cell death and is a target for
cancer immunotherapy. Nat Commun. 12:8322021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Selby MJ, Engelhardt JJ, Quigley M,
Henning KA, Chen T, Srinivasan M and Korman AJ: Anti-CTLA-4
antibodies of IgG2a isotype enhance antitumor activity through
reduction of intratumoral regulatory T cells. Cancer Immunol Res.
1:32–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jiang X, Li L, Li Y and Li Q: Molecular
mechanisms and countermeasures of immunotherapy resistance in
malignant tumor. J Cancer. 10:1764–1771. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tian H, Cao J, Li B, Nice EC, Mao H, Zhang
Y and Huang C: Managing the immune microenvironment of
osteosarcoma: The outlook for osteosarcoma treatment. Bone Res.
11:112023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Starska-Kowarska K: The role of different
immunocompetent cell populations in the pathogenesis of head and
neck cancer-regulatory mechanisms of pro- and anti-cancer activity
and their impact on immunotherapy. Cancers (Basel). 15:16422023.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li C, Jiang P, Wei S, Xu X and Wang J:
Regulatory T cells in tumor microenvironment: New mechanisms,
potential therapeutic strategies and future prospects. Mol Cancer.
19:1162020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Denize T, Jegede OA, Matar S, El Ahmar N,
West DJ, Walton E, Bagheri AS, Savla V, Laimon YN, Gupta S, et al:
PD-1 expression on intratumoral regulatory T cells is associated
with lack of benefit from Anti-PD-1 therapy in metastatic
clear-cell renal cell carcinoma patients. Clin Cancer Res.
30:803–813. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Merchant MS, Melchionda F, Sinha M, Khanna
C, Helman L and Mackall CL: Immune reconstitution prevents
metastatic recurrence of murine osteosarcoma. Cancer Immunol
Immunother. 56:1037–1046. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Han Q, Shi H and Liu F: CD163(+) M2-type
tumor-associated macrophage support the suppression of
tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol.
34:101–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gallina G, Dolcetti L, Serafini P, De
Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I,
Zanovello P, et al: Tumors induce a subset of inflammatory
monocytes with immunosuppressive activity on CD8+ T cells. J Clin
Invest. 116:2777–2790. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Munder M: Arginase: An emerging key player
in the mammalian immune system. Br J Pharmacol. 158:638–651. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yang Y, Li C, Liu T, Dai X and Bazhin AV:
Myeloid-derived suppressor cells in tumors: from mechanisms to
antigen specificity and microenvironmental regulation. Front
Immunol. 11:13712020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM,
West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC and
DeNardo DG: CSF1/CSF1R blockade reprograms tumor-infiltrating
macrophages and improves response to T-cell checkpoint
immunotherapy in pancreatic cancer models. Cancer Res.
74:5057–5069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
DeNardo DG, Brennan DJ, Rexhepaj E,
Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD,
Junaid SA, et al: Leukocyte complexity predicts breast cancer
survival and functionally regulates response to chemotherapy.
Cancer Discov. 1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hashimoto M, Kamphorst AO, Im SJ, Kissick
HT, Pillai RN, Ramalingam SS, Araki K and Ahmed R: CD8 T cell
exhaustion in chronic infection and cancer: Opportunities for
interventions. Annu Rev Med. 69:301–318. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Depuydt MAC, Schaftenaar FH, Prange KHM,
Boltjes A, Hemme E, Delfos L, de Mol J, de Jong MJM, Kleijn MNA,
Peeters JAHM, et al: Single-cell T cell receptor sequencing of
paired human atherosclerotic plaques and blood reveals
autoimmune-like features of expanded effector T cells. Nat
Cardiovasc Res. 2:112–125. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shin J, O'Brien TF, Grayson JM and Zhong
XP: Differential regulation of primary and memory CD8 T cell immune
responses by diacylglycerol kinases. J Immunol. 188:2111–2117.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu
L and Zhao LJ: Impact of lactate on immune cell function in the
tumor microenvironment: Mechanisms and therapeutic perspectives.
Front Immunol. 16:15633032025. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Leone RD, Sun IM, Oh MH, Sun IH, Wen J,
Englert J and Powell JD: Inhibition of the adenosine A2a receptor
modulates expression of T cell coinhibitory receptors and improves
effector function for enhanced checkpoint blockade and ACT in
murine cancer models. Cancer Immunol Immunother. 67:1271–1284.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Heger L, Hatscher L, Liang C, Lehmann CHK,
Amon L, Lühr JJ, Kaszubowski T, Nzirorera R, Schaft N, Dörrie J, et
al: XCR1 expression distinguishes human conventional dendritic cell
type 1 with full effector functions from their immediate
precursors. Proc Natl Acad Sci USA. 120:e23003431202023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ohno Y, Kitamura H, Takahashi N, Ohtake J,
Kaneumi S, Sumida K, Homma S, Kawamura H, Minagawa N, Shibasaki S
and Taketomi A: IL-6 down-regulates HLA class II expression and
IL-12 production of human dendritic cells to impair activation of
antigen-specific CD4(+) T cells. Cancer Immunol Immunother.
65:193–204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Oba T, Long MD, Keler T, Marsh HC,
Minderman H, Abrams SI, Liu S and Ito F: Overcoming primary and
acquired resistance to anti-PD-L1 therapy by induction and
activation of tumor-residing cDC1s. Nat Commun. 11:54152020.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ying H, Li ZQ, Li MP and Liu WC:
Metabolism and senescence in the immune microenvironment of
osteosarcoma: Focus on new therapeutic strategies. Front Endocrinol
(Lausanne). 14:12176692023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Bogdanov A, Bogdanov A, Chubenko V, Volkov
N, Moiseenko F and Moiseyenko V: Tumor acidity: From hallmark of
cancer to target of treatment. Front Oncol. 12:9791542022.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Muller AJ, DuHadaway JB, Donover PS,
Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine
2,3-dioxygenase, an immunoregulatory target of the cancer
suppression gene Bin1, potentiates cancer chemotherapy. Nat Med.
11:312–319. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bopp T, Becker C, Klein M, Klein-Hessling
S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt
S, et al: Cyclic adenosine monophosphate is a key component of
regulatory T cell-mediated suppression. J Exp Med. 204:1303–1310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai
W, Li J, Liao T, Li C and He J: The epigenetic hallmarks of immune
cells in cancer. Mol Cancer. 24:662025. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu W, Long Q, Zhang W, Zeng D, Hu B, Liu
S and Chen L: miRNA-221-3p derived from M2-polarized
tumor-associated macrophage exosomes aggravates the growth and
metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis. Aging
(Albany NY). 13:19760–19775. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hou Y, Zak J, Shi Y, Pratumchai I, Dinner
B, Wang W, Qin K, Weber EW, Teijaro JR and Wu P: Transient EZH2
suppression by tazemetostat during in vitro expansion maintains
T-cell stemness and improves adoptive T-cell therapy. Cancer
Immunol Res. 13:47–65. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Le Cesne A, Marec-Berard P, Blay JY,
Gaspar N, Bertucci F, Penel N, Bompas E, Cousin S, Toulmonde M,
Bessede A, et al: Programmed cell death 1 (PD-1) targeting in
patients with advanced osteosarcomas: Results from the PEMBROSARC
study. Eur J Cancer. 119:151–157. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Davis KL, Fox E, Merchant MS, Reid JM,
Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ and Mackall
CL: Nivolumab in children and young adults with relapsed or
refractory solid tumours or lymphoma (ADVL1412): A multicentre,
open-label, single-arm, phase 1–2 trial. Lancet Oncol. 21:541–550.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Davis KL, Fox E, Isikwei E, Reid JM, Liu
X, Minard CG, Voss S, Berg SL, Weigel BJ and Mackall CL: A phase
I/II trial of nivolumab plus ipilimumab in children and young
adults with relapsed/refractory solid tumors: A children's oncology
group study ADVL1412. Clin Cancer Res. 28:5088–5097. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Boye K, Longhi A, Guren T, Lorenz S, Næss
S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, et al:
Pembrolizumab in advanced osteosarcoma: Results of a single-arm,
open-label, phase 2 trial. Cancer Immunol Immunother. 70:2617–2624.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Palmerini E, Pousa AL, Grignani G, Redondo
A, Hindi N, Provenzano S, Sebio A, Martin JA, Valverde C, Trufero
JM, et al: Nivolumab and sunitinib in patients with advanced bone
sarcomas: A multicenter, single-arm, phase 2 trial. Cancer.
131:e356282025. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yang C, Lai Y, Wang J, Chen Q, Pan Q, Xu
C, Mo P, Guo G, Chen R, Liu N and Wu Y: Spatial heterogeneity of
PD-1/PD-L1 defined osteosarcoma microenvironments at single-cell
spatial resolution. Lab Invest. 104:1021432024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Jiang K, Li J, Zhang J, Wang L, Zhang Q,
Ge J, Guo Y, Wang B, Huang Y, Yang T, et al: SDF-1/CXCR4 axis
facilitates myeloid-derived suppressor cells accumulation in
osteosarcoma microenvironment and blunts the response to anti-PD-1
therapy. Int Immunopharmacol. 75:1058182019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Toda Y, Kohashi K, Yamada Y, Yoshimoto M,
Ishihara S, Ito Y, Iwasaki T, Yamamoto H, Matsumoto Y and Nakashima
Y: PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in
osteosarcoma patients: Comparative study of primary and metastatic
lesions. J Cancer Res Clin Oncol. 146:2607–2620. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Ribatti D: Mast cells and resistance to
immunotherapy in cancer. Arch Immunol Ther Exp (Warsz). 71:112023.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Lee AQ, Hao C, Pan M, Ganjoo KN and Bui
NQ: Histologic and immunologic factors associated with response to
immune checkpoint inhibitors in advanced sarcoma. Clin Cancer Res.
31:678–684. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Huang X, Park H, Greene J, Pao J, Mulvey
E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, et al: IGF1R- and
ROR1-Specific CAR T cells as a potential therapy for high risk
sarcomas. PLoS One. 10:e01331522015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Majzner RG, Theruvath JL, Nellan A,
Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota
C, et al: CAR T cells targeting B7-H3, a pan-cancer antigen,
demonstrate potent preclinical activity against pediatric solid
tumors and brain tumors. Clin Cancer Res. 25:2560–2574. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Talbot LJ, Chabot A, Funk A, Nguyen P,
Wagner J, Ross A, Tillman H, Davidoff A, Gottschalk S and DeRenzo
C: A novel orthotopic implantation technique for osteosarcoma
produces spontaneous metastases and illustrates dose-dependent
efficacy of B7-H3-CAR T cells. Front Immunol. 12:6917412021.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lake JA, Woods E, Hoffmeyer E, Schaller
KL, Cruz-Cruz J, Fernandez J, Tufa D, Kooiman B, Hall SC, Jones D,
et al: Directing B7-H3 chimeric antigen receptor T cell homing
through IL-8 induces potent antitumor activity against pediatric
sarcoma. J Immunother Cancer. 12:e0092212024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Talbot LJ, Chabot A, Ross AB, Beckett A,
Nguyen P, Fleming A, Chockley PJ, Shepphard H, Wang J, Gottschalk S
and DeRenzo C: Redirecting B7-H3.CAR T cells to chemokines
expressed in osteosarcoma enhances homing and antitumor activity in
preclinical models. Clin Cancer Res. 30:4434–4449. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang
C and Tao H: Anti-CD166/4-1BB chimeric antigen receptor T cell
therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res.
38:1682019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Charan M, Dravid P, Cam M, Audino A, Gross
AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ
and Cam H: GD2-directed CAR-T cells in combination with
HGF-targeted neutralizing antibody (AMG102) prevent primary tumor
growth and metastasis in Ewing sarcoma. Int J Cancer.
146:3184–3195. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Englisch A, Altvater B, Kailayangiri S,
Hartmann W and Rossig C: VEGFR2 as a target for CAR T cell therapy
of Ewing sarcoma. Pediatr Blood Cancer. 67:e283132020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hsu K, Middlemiss S, Saletta F, Gottschalk
S, McCowage GB and Kramer B: Chimeric antigen receptor-modified T
cells targeting EphA2 for the immunotherapy of paediatric bone
tumours. Cancer Gene Ther. 28:321–334. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lu YJ, Chu H, Wheeler LW, Nelson M,
Westrick E, Matthaei JF, Cardle II, Johnson A, Gustafson J, Parker
N, et al: Preclinical evaluation of bispecific adaptor molecule
controlled folate receptor CAR-T cell therapy with special focus on
pediatric malignancies. Front Oncol. 9:1512019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Watanabe Y, Tsukahara T, Murata K, Hamada
S, Kubo T, Kanaseki T, Hirohashi Y, Emori M, Teramoto A,
Nakatsugawa M, et al: Development of CAR-T cells specifically
targeting cancer stem cell antigen DNAJB8 against solid tumours. Br
J Cancer. 128:886–895. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Mensali N, Köksal H, Joaquina S, Wernhoff
P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L,
Juzeniene A, et al: ALPL-1 is a target for chimeric antigen
receptor therapy in osteosarcoma. Nat Commun. 14:33752023.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Wickman E, Lange S, Wagner J, Ibanez J,
Tian L, Lu M, Sheppard H, Chiang J, Koo SC, Vogel P, et al: IL-18R
supported CAR T cells targeting oncofetal tenascin C for the
immunotherapy of pediatric sarcoma and brain tumors. J Immunother
Cancer. 12:e0097432024. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao
Q, Dao L, Xia X, Wall FN, Zhang Z, et al: Cell membrane-anchored
and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating
large and heterogeneous solid tumors. J Immunother Cancer.
10:e0036332022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao
LH, Zhang W, Zhang S, Xia X, Gorlick R and Li S: Membrane-anchored
and tumor-targeted IL12 (attIL12)-PBMC therapy for osteosarcoma.
Clin Cancer Res. 28:3862–3873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Hui X, Farooq MA, Chen Y, Ajmal I, Ren Y,
Xue M, Ji Y, Du B, Wu S and Jiang W: A novel strategy of
co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in
osteosarcoma. Front Immunol. 15:14620762024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Adeshakin AO, Shi H, Perry SS, Sheppard H,
Nguyen P, Sun X, Zhou P, Métais JY, Cunningham T, Anil KC, et al:
Targeting Regnase-1 unleashes CAR T cell antitumor activity for
osteosarcoma and creates a proinflammatory tumor microenvironment.
bioRxiv. 23:2025.05.20.650777. 2025.
|
|
121
|
Hidalgo L, Somovilla-Crespo B,
Garcia-Rodriguez P, Morales-Molina A, Rodriguez-Milla MA and
Garcia-Castro J: Switchable CAR T cell strategy against
osteosarcoma. Cancer Immunol Immunother. 72:2623–2633. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wang Z, Yan N, Sheng H, Xiao Y, Sun J and
Cao C: Single-cell transcriptomic analysis reveals an
immunosuppressive network between POSTN CAFs and ACKR1 ECs in
TKI-resistant lung cancer. Cancer Genomics Proteomics. 21:65–78.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Altvater B, Kailayangiri S, Lanuza LF,
Urban K, Greune L, Flügge M, Meltzer J, Farwick N, König S, Görlich
D, et al: HLA-G and HLA-E immune checkpoints are widely expressed
in ewing sarcoma but have limited functional impact on the effector
functions of antigen-specific CAR T cells. Cancers (Basel).
13:28572021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Pezzella M, Quintarelli C, Quadraccia MC,
Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera
A, D'Amore ML, et al: Tumor-derived G-CSF induces an
immunosuppressive microenvironment in an osteosarcoma model,
reducing response to CAR.GD2 T-cells. J Hematol Oncol. 17:1272024.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kaczanowska S, Murty T, Alimadadi A,
Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA,
Baskar R, Wu CJ, et al: Immune determinants of CAR-T cell expansion
in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer
Cell. 42:35–51.e8. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Arnett AB and Heczey A: GD2-CAR CAR T
cells in patients with osteosarcoma and neuroblastoma-it's not only
the T cells that matter. Cancer Cell. 42:8–10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lu YC, Parker LL, Lu T, Zheng Z, Toomey
MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, et al:
Treatment of patients with metastatic cancer using a major
histocompatibility complex class II-restricted T-cell receptor
targeting the cancer germline antigen MAGE-A3. J Clin Oncol.
35:3322–3329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hamada S, Tsukahara T, Watanabe Y, Murata
K, Mizue Y, Kubo T, Kanaseki T, Hirohashi Y, Emori M, Nakatsugawa
M, et al: Development of T cell receptor-engineered T cells
targeting the sarcoma-associated antigen papillomavirus binding
factor. Cancer Sci. 115:24–35. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Ketola A, Hinkkanen A, Yongabi F, Furu P,
Määttä AM, Liimatainen T, Pirinen R, Björn M, Hakkarainen T,
Mäkinen K, et al: Oncolytic Semliki forest virus vector as a novel
candidate against unresectable osteosarcoma. Cancer Res.
68:8342–8350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hingorani P, Zhang W, Lin J, Liu L, Guha C
and Kolb EA: Systemic administration of reovirus (Reolysin)
inhibits growth of human sarcoma xenografts. Cancer. 117:1764–1774.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Christie JD, Appel N, Zhang L, Lowe K,
Kilbourne J, Daggett-Vondras J, Elliott N, Lucas AR, Blattman JN,
Rahman MM and McFadden G: Systemic delivery of mLIGHT-armed myxoma
virus is therapeutic for later-stage syngeneic murine lung
metastatic osteosarcoma. Cancers (Basel). 14:3372022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Laborda E, Puig-Saus C, Rodriguez-García
A, Moreno R, Cascalló M, Pastor J and Alemany R: A pRb-responsive,
RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus
for application in veterinary oncology. Mol Ther. 22:986–998. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Musser ML, Berger EP, Tripp CD, Clifford
CA, Bergman PJ and Johannes CM: Safety evaluation of the canine
osteosarcoma vaccine, live Listeria vector. Vet Comp Oncol.
19:92–98. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chen A, Qiu Y, Yen YT, Wang C, Wang X, Li
C, Wei Z, Li L, Yu L, Liu F and Li R: Expression of cancer-testis
antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in bone and soft
tissue sarcomas: The experience from a single center in China.
Cancer Med. 14:e707502025. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gu J, Ji Z, Li D and Dong Q: Proliferation
inhibition and apoptosis promotion by dual silencing of VEGF and
Survivin in human osteosarcoma. Acta Biochim Biophys Sin
(Shanghai). 51:59–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhang Y, Cheng H, Li W, Wu H and Yang Y:
Highly-expressed P2X7 receptor promotes growth and metastasis of
human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and
mTOR/HIF1α/VEGF signaling. Int J Cancer. 145:1068–1082. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Dong J, Chai X, Xue Y, Shen S, Chen Z,
Wang Z, Yinwang E, Wang S, Chen L, Wu F, et al: ZIF-8-encapsulated
pexidartinib delivery via targeted peptide-modified M1 macrophages
attenuates MDSC-mediated immunosuppression in osteosarcoma. Small.
20:e23090382024. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Gutiérrez LM, Alvarez MV, Yang Y, Spinelli
F, Cantero MJ, Alaniz L, García MG, Kleinerman ES, Correa A and
Bolontrade MF: Up-regulation of pro-angiogenic molecules and events
does not relate with an angiogenic switch in metastatic
osteosarcoma cells but to cell survival features. Apoptosis.
26:447–459. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
LShijie L, Zhen P, Kang Q, Hua G,
Qingcheng Y and Dongdong C: Deregulation of CLTC interacts with
TFG, facilitating osteosarcoma via the TGF-beta and AKT/mTOR
signaling pathways. Clin Transl Med. 11:e3772021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Xie L, Liang X, Xu J, Sun X, Liu K, Sun K,
Li Y, Tang X, Li X, Zhan X, et al: Exploratory study of an
anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or
recurrent osteosarcoma and alveolar soft part sarcoma: A report
from Chinese sarcoma study group (TQB2858-Ib-02). BMC Cancer.
23:8682023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Hu J, Lazar AJ, Ingram D, Wang WL, Zhang
W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, et al: Cell
membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys
cancer-associated fibroblasts and disrupts extracellular matrix in
heterogenous osteosarcoma xenograft models. J Immunother Cancer.
12:e0069912024. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kong D, Ying B, Zhang J and Ying H: The
anti-osteosarcoma property of ailanthone through regulation of
miR-126/VEGF-A axis. Artif Cells Nanomed Biotechnol. 47:3913–3919.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li B, Dang X, Duan J, Zhang G, Zhang J and
Song Q: SIX4 upregulates IDH1 and metabolic reprogramming to
promote osteosarcoma progression. J Cell Mol Med. 27:259–265. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Shan J, Lin Z, Rashid H, Huang P, Qiang L,
Liu Y, Shen G, Li Y, Cui J, Su Z, et al: A novel therapeutic
strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.
Biomark Res. 13:872025. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Taylor AM, Sheng J, Ng PKS, Harder JM,
Kumar P, Ahn JY, Cao Y, Dzis AM, Jillette NL, Goodspeed A, et al:
Immunosuppressive tumor microenvironment of osteosarcoma. Cancers
(Basel). 17:21172025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Gassmann H, Schneider K, Evdokimova V,
Ruzanov P, Schober SJ, Xue B, von Heyking K, Thiede M, Richter GHS,
Pfaffl MW, et al: Ewing sarcoma-derived extracellular vesicles
impair dendritic cell maturation and function. Cells. 10:20812021.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wang L, Dou X, Xie L, Zhou X, Liu Y, Liu J
and Liu X: Metabolic landscape of osteosarcoma: Reprogramming of
lactic acid metabolism and metabolic communication. Front Biosci
(Landmark Ed). 29:832024. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Wang Y, Wang X, Liu Y, Xu J, Zhu J, Zheng
Y and Qi Q: A novel hypoxia- and lactate metabolism-related
prognostic signature to characterize the immune landscape and
predict immunotherapy response in osteosarcoma. Front Immunol.
15:14670522024. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zhu J, Simayi N, Wan R and Huang W: CAR T
targets and microenvironmental barriers of osteosarcoma.
Cytotherapy. 24:567–576. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Nguyen DT, Ogando-Rivas E, Liu R, Wang T,
Rubin J, Jin L, Tao H, Sawyer WW, Mendez-Gomez HR, Cascio M, et al:
CAR T cell locomotion in solid tumor microenvironment. Cells.
11:19742022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chim LK, Williams IL, Bashor CJ and Mikos
AG: Tumor-associated macrophages induce inflammation and drug
resistance in a mechanically tunable engineered model of
osteosarcoma. Biomaterials. 296:1220762023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Cheng JN, Jin Z, Su C, Jiang T, Zheng X,
Guo J, Li X, Chu H, Jia J, Zhou Q, et al: Bone metastases diminish
extraosseous response to checkpoint blockade immunotherapy through
osteopontin-producing osteoclasts. Cancer Cell. 43:1093–1107.e9.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Martinov T, McKenna KM, Tan WH, Collins
EJ, Kehret AR, Linton JD, Olsen TM, Shobaki N and Rongvaux A:
Building the next generation of humanized hemato-lymphoid system
mice. Front Immunol. 12:6438522021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yin L and Wang XJ, Chen DX, Liu XN and
Wang XJ: Humanized mouse model: A review on preclinical
applications for cancer immunotherapy. Am J Cancer Res.
10:4568–4584. 2020.PubMed/NCBI
|
|
155
|
Bacac M, Klein C and Umana P: CEA TCB: A
novel head-to-tail 2:1 T cell bispecific antibody for treatment of
CEA-positive solid tumors. Oncoimmunology. 5:e12034982016.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Lehmann S, Perera R, Grimm HP, Sam J,
Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober
A, Zielonka J, et al: In vivo fluorescence imaging of the activity
of CEA TCB, a novel T-Cell bispecific antibody, reveals highly
specific tumor targeting and fast induction of T-Cell-mediated
tumor killing. Clin Cancer Res. 22:4417–4427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Sun Z, Gu M, Yang Z, Shi L, Zhao L, Zheng
M, Wang Y, Zhang W, Han K and Tang N: Application of humanized mice
in the safety experiments of antibody drugs. Animal Model Exp Med.
8:1023–1032. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Gail LM, Schell KJ, Łacina P, Strobl J,
Bolton SJ, Ulriksen ES, Bogunia-Kubik K, Greinix H, Crossland RE,
Inngjerdingen M and Stary G: Complex interactions of cellular
players in chronic Graft-versus-Host Disease. Front Immunol.
14:11994222023. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Jackett KN, DaPonte DL, Soman P and Horton
JA: Modeling the effects of radiation on the bone tumor
microenvironment: Opportunities for exploring combination therapies
in microphysiologic systems. Cell Mol Biol Lett. 30:972025.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zheng BW, Zheng BY, Niu HQ, Yang YF, Zhu
GQ, Li J, Zhang TL and Zou MX: Tumor growth rate in spinal giant
cell tumors of bone and association with the immune
microenvironment and denosumab treatment responsiveness: A
multicenter study. Neurosurgery. 92:524–537. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Cheng X, Peng T, Chu T, Yang Y, Liu J, Gao
Q, Cao C and Wei J: Application of single-cell and spatial omics in
deciphering cellular hallmarks of cancer drug response and
resistance. J Hematol Oncol. 18:702025. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Chen J, Chen F, Zhang H, Hu Y, Zhou X,
Weng X, Bao G and Ding X: Multi-omics-based construction of a
palmitoylation-driven prognostic model reveals tumor immune
phenotypes in osteosarcoma. Discov Oncol. 16:15442025. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Yu B, Pacureanu A, Olivier C, Cloetens P
and Peyrin F: Assessment of the human bone lacuno-canalicular
network at the nanoscale and impact of spatial resolution. Sci Rep.
10:45672020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Lu T, Park S, Zhu J, Wang Y, Zhan X, Wang
X, Wang L, Zhu H and Wang T: Overcoming Expressional drop-outs in
lineage reconstruction from single-cell RNA-sequencing data. Cell
Rep. 34:1085892021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Leipold MD, Obermoser G, Fenwick C,
Kleinstuber K, Rashidi N, McNevin JP, Nau AN, Wagar LE, Rozot V,
Davis MM, et al: Comparison of CyTOF assays across sites: Results
of a six-center pilot study. J Immunol Methods. 453:37–43. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Lacinski RA, Dziadowicz SA, Roth CA, Ma L,
Melemai VK, Fitzpatrick B, Chaharbakhshi E, Heim T, Lohse I,
Schoedel KE, et al: Spatial multiplexed immunofluorescence analysis
reveals coordinated cellular networks associated with overall
survival in metastatic osteosarcoma. Bone Res. 12:552024.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Krieg C, Nowicka M, Guglietta S, Schindler
S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP,
Becher B, et al: High-dimensional single-cell analysis predicts
response to anti-PD-1 immunotherapy. Nat Med. 24:144–153. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Jiang Y, Wang J, Sun M, Zuo D, Wang H,
Shen J, Jiang W, Mu H, Ma X, Yin F, et al: Multi-omics analysis
identifies osteosarcoma subtypes with distinct prognosis indicating
stratified treatment. Nat Commun. 13:72072022. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Keung EZ, Burgess M, Salazar R, Parra ER,
Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S,
Riedel RF, et al: Correlative analyses of the SARC028 trial reveal
an association between sarcoma-associated immune infiltrate and
response to pembrolizumab. Clin Cancer Res. 26:1258–1266. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Gu L, Peng C, Liang Q, Huang Q, Lv D, Zhao
H, Zhang Q, Zhang Y, Zhang P, Li S, et al: Neoadjuvant toripalimab
plus axitinib for clear cell renal cell carcinoma with inferior
vena cava tumor thrombus: NEOTAX, a phase 2 study. Signal Transduct
Target Ther. 9:2642024. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Brekken C, Bruland ØS and de Lange Davies
C: Interstitial fluid pressure in human osteosarcoma xenografts:
Significance of implantation site and the response to intratumoral
injection of hyaluronidase. Anticancer Res. 20:3503–3512.
2000.PubMed/NCBI
|
|
172
|
Wu H, Luo Y, Xu D, Ke X and Ci T: Low
molecular weight heparin modified bone targeting liposomes for
orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Int J Biol Macromol. 164:2583–2597. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin
S, Wang X, Zhao Y, Ji Z, Zink JI and Nel AE: Codelivery of an
optimal drug/siRNA combination using mesoporous silica
nanoparticles to overcome drug resistance in breast cancer in vitro
and in vivo. ACS Nano. 7:994–1005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Kontulainen SA, Macdonald HM and McKay HA:
Change in cortical bone density and its distribution differs
between boys and girls during puberty. J Clin Endocrinol Metab.
91:2555–2561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Dai XM, Ryan GR, Hapel AJ, Dominguez MG,
Russell RG, Kapp S, Sylvestre V and Stanley ER: Targeted disruption
of the mouse colony-stimulating factor 1 receptor gene results in
osteopetrosis, mononuclear phagocyte deficiency, increased
primitive progenitor cell frequencies, and reproductive defects.
Blood. 99:111–120. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Joseph GJ, Vecchi Iii LA, Uppuganti S,
Kane JF, Durdan M, Hill P, McAdoo AG, Tanaka H, Kell D, Searcy MB,
et al: Programmed cell death protein 1 (PD-1) blockade regulates
skeletal remodeling in a sex- and age-dependent manner. J Bone
Miner Res. 40:950–964. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
DeSelm C, Palomba ML, Yahalom J, Hamieh M,
Eyquem J, Rajasekhar VK and Sadelain M: Low-dose radiation
conditioning enables CAR T cells to mitigate antigen escape. Mol
Ther. 26:2542–2552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Yu D, Kahen E, Cubitt CL, McGuire J,
Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM and Reed DR:
Identification of synergistic, clinically achievable, combination
therapies for osteosarcoma. Sci Rep. 5:169912015. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Gargett T, Ebert LM, Truong NTH, Kollis
PM, Sedivakova K, Yu W, Yeo ECF, Wittwer NL, Gliddon BL, Tea MN, et
al: GD2-targeting CAR-T cells enhanced by transgenic IL-15
expression are an effective and clinically feasible therapy for
glioblastoma. J Immunother Cancer. 10:e0051872022. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Rahouma M, Karim NA, Baudo M, Yahia M,
Kamel M, Eldessouki I, Abouarab A, Saad I, Elmously A, Gray KD, et
al: Cardiotoxicity with immune system targeting drugs: A
meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical
trials. Immunotherapy. 11:725–735. 2019. View Article : Google Scholar : PubMed/NCBI
|
